The herpes simplex virus type 1 (HSV-1) virion, like that of all herpesviruses, consists of an envelope surrounding an icosahedral capsid shell which contains a double-stranded linear DNA genome. Between the proteinaceous capsid and lipid envelope lies an assemblage of more than 20 viral proteins termed the tegument. Upon entry, some tegument proteins are released into the cytosol to help prime the cell for infection. For example, the virion host shutoff (vhs) protein degrades mRNA to favor viral gene expression (20, 26) , and VP16 (viral protein 16, also designated ␣-TIF) redirects host transactivators to viral promoters (19, 25) . Once the virus has entered the cell, the cytoplasmic DNA-containing capsid traffics toward the host nucleus by using the microtubule motor dynein (33) . Upon engaging a nuclear pore, the HSV-1 genome exits the capsid and enters the nucleoplasm (3, 34) . Expression of viral genes is temporally regulated, starting with immediate-early (␣) genes and followed sequentially by early (␤) and late (␥) genes (16, 17) . Most ␣ genes encode regulatory proteins. These include ICP4 (infected cell protein 4), which transcriptionally activates other genes, and ICP27, which augments viral gene expression at both pre-and posttranscriptional levels. Gene products from the ␤ class (e.g., ICP8, an essential DNA binding protein) are involved in DNA replication, whereas the ␥ genes encode structural proteins, like the major capsid protein VP5. Viral DNA (vDNA) replication occurs during the transition from ␤ to ␥ gene expression; the ␥ genes can be further subdivided into ␥ 1 (leaky late) and ␥ 2 (true late). This subdivision stems from a dependence on vDNA synthesis. If vDNA replication is blocked, such as with the use of the DNA polymerase inhibitor phosphonoacetic acid (PAA), ␥ 1 gene expression is diminished and ␥ 2 gene expression is precluded.
As the virus enters the cell, cellular signaling events mediate a transition in host cell functionality that favors viral propagation. For example, interaction of viral glycoprotein D (gD) with a tumor necrosis factor (TNF) receptor known as herpesvirus entry mediator (HVEM; also known as HveA and TNFRSF14) induces a transient activation of NF-B (nuclear factor B) (32) . This induction, lasting approximately 2 h postinfection (hpi), is likely stimulated through the TNF receptor-associated factor (TRAF) signal transduction pathway and is dependent on cell type (e.g., the cell must express the appropriate receptor). It has also been reported that the tegument protein U L 37 activates NF-B through an interaction with TRAF6 (22) . In addition to this transient activation of NF-B, there is a second wave of NF-B activation that requires de novo HSV-1 gene expression (2) . This wave of NF-B activation initiates at approximately 6 hpi and has been shown to require the ␣ gene product ICP27 (9) . NF-B is a transcriptional regulator found in almost every cell type and is normally activated in response to cell stress, such as inflammation or viral infection (reviewed in references 11, 12, and 18). While some viruses block NF-B activation (for a review, see reference 14), HSV-1 requires activation of NF-B for efficient infection (24) . This requirement has been demonstrated by use of dominant negative repressors (1, 8, 24) , knockout cell lines (8) , and inhibitory drugs (6) .
This study focuses on U L 31 of HSV-1. Deletion of U L 31 decreases viral titers to various degrees in different cell lines: up to 1,000-fold in Vero cells, and at least 10-fold in rabbit skin cells (RSC) (21) . pU L 31 (the gene product of U L 31) plays an important role in nuclear egress, because viral capsids largely fail to bud through the inner nuclear membrane in cells infected with U L 31 deletion mutants (4, 28) . A similar phenotype is observed upon deletion of pU L 31's interaction partner, pU L 34 (31) , an integral membrane protein that localizes to the inner nuclear membrane in wild-type virus infections. Nuclear rim targeting of pU L 31 is dependent on expression of pU L 34. Without this binding partner, the bulk of pU L 31 localizes in the nucleoplasm (28) . Both U L 31 and U L 34 are also required for alteration of the nuclear lamina (27) , which is composed largely of a meshwork of intermediate filaments lining the inner surface of the inner nuclear membrane. The nuclear lamina is required for maintaining the structure of the nucleus, and its pU L 31/pU L 34-dependent perforation during HSV infection is believed to promote access of nucleocapsids to the inner nuclear membrane for envelopment. Both pU L 34 and pU L 31 are incorporated into the virion during budding through the inner nuclear membrane into the perinuclear space. The envelope of this perinuclear virion is lost upon fusion with the outer nuclear membrane as the capsid enters the cytosol; thus, pU L 31 is not a component of the final extracellular virion (7, 23, 29) . Deletion of U L 31 also diminishes vDNA replication and packaging (4) .
In the current study, U L 31 expression was found to be required for efficient NF-B activation and optimal viral protein expression. The latter observation may help explain pU L 31's effects on DNA packaging, which require late viral gene products. The effects on gene expression were shown to be independent of pU L 31's interaction partner pU L 34. Although U L 31 has been designated a true late gene based on sensitivity of its mRNA to 1-␤-D-arabinofuranosylthymine (15), we have found that pU L 31 is detectable at low levels as early as 2 h postinfection. This observation suggests that pU L 31 made de novo accounts for its effects on viral protein expression.
MATERIALS AND METHODS

Viruses and cells.
Wild-type HSV-1 strain F [HSV-1(F)], ⌬U L 31, and ⌬U L 31-R were provided by Bernard Roizman and have been described previously (4, 5) . ⌬U L 34 was provided by Richard Roller and has been described previously (31) . d27-1, the ICP27-null virus, and the ICP27-complementing cell line V27 were provided by Stephen Rice and have been described previously (30) . Wild-type virus stocks [HSV-1(F) and ⌬U L 31-R] were propagated and titers were determined on Vero cell monolayers, whereas rabbit skin cells engineered to express pU L 31 (21) were used to propagate and determine the titers of the U L 31 deletion virus, ⌬U L 31. The cell lines were maintained in growth medium, consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 125 units/ml penicillin, 0.125 mg/ml streptomycin, and 10% newborn calf serum. Two different viral stocks of the U L 31 deletion virus were used in the reported studies. These stocks produced at least 1,000-fold more viral plaques per ml on monolayers of the complementing cell line than on Vero cells. For all experiments, cells were overlaid with 199V medium (DMEM supplemented with 1% newborn calf serum) after infection and monitored for cytopathic effects until harvesting or fixation.
Immunoblot analyses. Mock-infected and HSV-1(F)-infected cells were washed once in phosphate-buffered saline (PBS) and then lysed in 100 l of 2ϫ sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer consisting of 100 mM Tris-Cl (pH 6.8), 200 mM dithiothreitol, 4% SDS, 20% glycerol, and 0.2% bromophenol blue. Lysates were sonicated and boiled for 5 min prior to loading. Samples were separated on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane (30 V for 3.5 h at 4°C). The membrane was blocked in 5% milk-TBST (1ϫ Tris-buffered saline plus 0.1% Tween) for 1 h at room temperature. The following primary antibodies were diluted in 5% bovine serum albumin (BSA) in TBST as follows: mouse anti-ICP4
(1:1,000; Rumbaugh-Goodwin Institute for Cancer Research, Plantation, FL), mouse anti-ICP27 (1:5,000; Virusys Corporation, Sykesville, MD), rabbit anti-ICP8 (1:10,000; a gift from Bill Ruyechan), mouse anti-gC (1:1,000; RumbaughGoodwin Institute for Cancer Research, Plantation, FL), rabbit anti-phospho Jun N-terminal kinase (p-JNK; 1:1,000; Cell Signaling 4668), rabbit anti-total JNK (1:1,000; Cell Signaling 9252), rabbit anti-IB␣ (1:1,000; Cell Signaling 9242), mouse anti-lamin A/C (1:1,000; Santa Cruz Biotechnology sc7292). Diluted primary antibodies were reacted with blocked membrane for either 1 h at room temperature or overnight at 4°C with gentle agitation. After extensive washing in PBS, bound primary antibody was detected by addition of anti-mouse (1:2,000; Santa Cruz Biotechnology) or anti-rabbit (1:2,000; Santa Cruz Biotechnology) horseradish peroxidase-conjugated secondary antibody diluted in 5% milk-TBST and visualized by enhanced chemiluminescence (Pierce) followed by exposure to X-ray film (Pierce). Image J was used for densitometry.
Immunofluorescence. Hep2 cells seeded on coverslips in a 12-well dish were either mock infected or infected with 10.0 PFU per cell of HSV-1(F), ⌬31, or ⌬31-R and fixed every hour between 1 and 10 h postinfection by washing cells once with PBS and treating with 3% paraformaldehyde (PFA) for 15 min at room temperature. The fixed cells were stained with Hoechst dye (2 g/ml in PBS; Invitrogen) for 15 min followed by immersion in 50 mM NH 4 Cl for 15 min to quench autofluorescence. The cells were permeabilized with 0.1% Triton X-100 for 2 min followed by a 10-min block in 10% human serum in PBS. Mouse anti-ICP4 (Rumbaugh-Goodwin Institute for Cancer Research, Plantation, FL) primary antibodies were diluted 1:100 in 1% BSA in PBS and incubated with the fixed cells for 30 min in a humidity chamber held at room temperature. After washing 3 times in excess PBS, the cells were reacted for 30 min in a humidity chamber with secondary antibodies, fluorescein isothiocyanate-conjugated antimouse IgG (Jackson Laboratories) diluted 1:100 in 1% BSA-PBS. The coverslips were then washed 3 times in PBS and dipped in double-distilled H 2 O before mounting on glass slides with mowiol plus 2.5% DABCO to prevent photobleaching. All digital images were taken using a Zeiss Axio Imager M1 fluorescence microscope and were processed with Adobe Photoshop software.
Drug treatments. In some experiments, Hep2 cells in a six-well dish were pretreated with 10 M cycloheximide (CHX) for 1 h at 37°C, 5% CO 2 or left untreated. After 1 h, cells were washed with versene (PBS plus 0.5 M EDTA) and infected with wild-type HSV-1(F) at a multiplicity of infection (MOI) of 10 PFU/cell or mock infected. Ten M CHX was included with the added virus for the appropriate wells, and the cells were rocked slowly for 1 h at 37°C to allow for viral attachment and entry. After the 1-h incubation, the virus or mock overlay was removed, the cells were washed with versene, and fresh 199V was added back to the cells (containing 10 M CHX where appropriate). At time zero the cells were returned to the 37°C, 5% CO 2 incubator until collected.
For experiments using PAA, Hep2 cells in a six-well dish were infected with HSV-1(F) at an MOI of 10 PFU/cell or mock infected. At the start of infection, 200 g/ml PAA was added to the appropriate wells. Cells were washed 12 h later, and total cell lysates were collected. For all drug treatment experiments, total cell lysates were collected as described in "Immunoblot analyses" above.
RESULTS
Infections with ⌬U L 31 but not ⌬U L 34 are delayed for ␣, ␤, and ␥ gene expression. It has been reported that ⌬U L 31 infections result in decreased viral DNA accumulation, cleavage, and packaging (4). The current studies were initiated to determine how pU L 31 might contribute to these activities, with the hypothesis that U L 31 might augment viral gene expression. Because pU L 31 interacts with pU L 34, we included a ⌬U L 34 virus in the experiment to determine if any detected phenotype was dependent upon the pU L 31-pU L 34 interaction. Hep2 cells were mock infected or infected with wild-type HSV-1(F), ⌬U L 31, or ⌬U L 34 viruses at an MOI of 10 PFU per cell. At 4 and 18 hpi, total cell lysates were collected and proteins were separated by SDS-PAGE as described in Materials and Methods. The results are shown in Fig. 1 . For this and subsequent immunoblot assays, quantification was done using Image J. Similar results were noted in Hep2 cells infected with the U L 31 deletion virus at up to 50 PFU per cell (data not shown).
Surprisingly, immunoblotting ( Fig. 1) showed that essen-tially no ICP4 (an ␣ gene product) or ICP8 (a ␤ gene product) accumulated to detectable levels by 4 hpi in cells infected with the ⌬U L 31 virus, whereas both proteins were detected at this time point in cells infected with either the wild-type HSV-1(F) or ⌬U L 34 viruses. At 4 hpi, ICP4 and ICP8 protein levels in the ⌬U L 31 infection were only 3% and 5%, respectively, of those seen from the infection with wild-type virus. Although both ICP4 and ICP8 protein levels increased in the lysate of the ⌬U L 31 infection by 18 hpi, the levels were only 55% and 41% of levels in HSV-1(F) infection. Protein levels of the ␥ 2 gene product gC in the ⌬U L 31 infection accumulated to only 34% of gC from infection with the wild-type HSV-1(F). For all cases, infections with the ⌬U L 34 virus resulted in protein levels similar to or higher than wild-type infection. We conclude that U L 31 is necessary for optimal expression of at least one member of each kinetic class of viral protein.
Because it has been shown that inhibition of NF-B activity by the drug resveratrol results in reduced levels of several ␣ gene mRNAs and undetectable levels of gC mRNA (6), we hypothesized that pU L 31 might augment viral protein expression by ensuring activation of the transcriptional regulator NF-B. To test this possibility, we probed immunoblots of total infected cell proteins with antibody to IB␣, the NF-B inhibitor. IB␣ binds NF-B in the cytosol, inhibiting its translocation into the nucleus and thus maintaining a pool of inactive (transcriptionally incompetent) NF-B (13, 18) . Upon NF-B activation, IB␣ is phosphorylated, polyubiquitinated, and finally degraded. Normally in HSV-1 infections, NF-B activation is observed as early as 6 hpi, and this activation can be measured by the concomitant absence of the NF-B repressor IB␣ (9) . As shown in Fig. 1 , IB␣ accumulated to similar levels at 4 hpi in all samples. At 18 hpi, IB␣ protein levels from HSV-1(F)-and ⌬U L 34-infected cells were 8% and 2% of mock-infected cells, whereas ⌬U L 31-infected cell lysates contained protein levels of IB␣ at 85% of the mock level. These data indicate that U L 31 plays a role in ensuring elimination of IB␣ in infected cells, and thus activation of NF-B.
We also examined relative levels of activated p-JNK and found that at 18 hpi the ⌬U L 31 virus induced levels of p-JNK that amounted to only 28% of the level detected from the wild-type HSV-1(F) infection. In contrast, levels of total JNK were similar in all lanes. Taken together, the results indicate that in addition to a viral protein expression deficiency, the ⌬U L 31 virus exhibits deficiencies in NF-B and JNK activation that are normally seen during HSV-1 infection.
NF-B and JNK activation are downregulated in ⌬U L 31 infections of different cell types. To determine if NF-B and JNK activation seen in the ⌬U L 31-infected Hep2 cells (Fig. 1 ) occurred in other cell types, RSC, Vero, HeLa, and Hep2 cells, as well as the ⌬U L 31-complementing cell line, clone 7 (an RSC derivative) were mock infected or infected with the ⌬U L 31, HSV-1(F), or ⌬U L 31-R (repair) viruses. All cell types were infected at an MOI of 10 PFU per cell, and total cell lysates were collected at 4, 8, 12, and 18 hpi as described in Materials and Methods. Equal amounts of proteins from each sample at each time point were separated by SDS-PAGE, transferred to nitrocellulose membranes, and reacted with antibody for IB␣ (the NF-B repressor), total JNK, and p-JNK as described in Materials and Methods. Sample loading was assessed by probing with an antibody directed against lamin A/C. Although the amounts loaded in each lane were consistent within samples from a given cell line, they varied somewhat between cell lines. Nevertheless, the consistency of loading between samples from each cell type enabled comparisons of protein expression by the different viruses in each cell type examined.
Overall, the results indicated a positive correlation between defects in protein synthesis in ⌬U L 31 infections (Fig. 1) and both decreased JNK and NF-B activation in the various cell lines (Fig. 2) as follows.
In the nonpermissive Hep2 and HeLa cell lines, IB␣ levels were similar upon infection with all viruses at 4 hpi, whereas at later time points IB␣ was downregulated to 36% and 34% of mock-infected cell levels in HSV-1(F) and ⌬U L 31-R, respectively. However, in cells infected with ⌬U L 31, IB␣ was downregulated to only 78% of mock levels. The differences were accentuated at 18 hpi, when IB␣ was downregulated to 15% and 7% of mock-infected cell levels for HSV-1(F) and ⌬U L 31-R, respectively, but downregulated to only 76% of mock levels in the ⌬U L 31 infection.
In HeLa cells, activated JNK was first detected at 8 hpi in cells infected with HSV-1(F) and ⌬U L 31-R, but in cells infected with ⌬U L 31 the p-JNK level was only 8% of that in cells infected with ⌬U L 31-R. Even at 18 hpi, the p-JNK level in ⌬U L 31-infected cells was only 15% of that in the ⌬U L 31-R infection. Although activated JNK was never abundant in Hep2 cells, it was first detected at 8 hpi with the wild-type virus. p-JNK levels were significantly lower at later time points (8%, 3%, and 0.4% of p-JNK levels in cells infected with ⌬U L 31-R at 8, 12, and 18 hpi, respectively).
Vero cells, unlike Hep2 and HeLa cells, exhibited easily detectable phosphorylated JNK as early as 4 hpi, although levels in cells infected with ⌬U L 31 were 46% of the level observed upon infection with ⌬U L 31-R. The differences in Total cell lysates were collected at 4 and 18 hpi. Proteins were denatured and separated by SDS-PAGE, transferred to a nitrocellulose membrane, and reacted with antibodies against ICP4, ICP8, gC, p-JNK, total JNK, IB␣, and lamin A/C, which was used as a loading control. Bound antibodies were revealed by reaction with appropriately conjugated antibodies, followed by chemiluminescence and exposure to X-ray film as described in Materials and Methods. Immunoblot signals of IB␣ were not as strong in RSC as in the other cell lines examined. Nevertheless, this cell line contained more IB␣ when mock infected or infected with ⌬U L 31 than in cells infected with the wild-type HSV-1(F) or ⌬U L 31-R. Compared to mock infection leves, IB␣ levels in HSV-1(F), ⌬U L 31, and ⌬U L 31-R were 19%, 167%, and 21%, respectively. The differences in IB␣ levels in the different virus infections were largely eliminated by 12 hpi, as the percentage of detectable IB␣ relative to the mock level were 3%, 16%, and 2% for HSV-1(F), ⌬U L 31, and ⌬U L 31-R, respectively. Very little activated JNK (p-JNK) was detected in RSC at any time point. Thus, rabbit skin cells were more permissive with respect to NF-B and JNK activation in the context of ⌬U L 31 than either Hep2 or HeLa cells.
In clone 7 cells, which partially rescue the U L 31 deletion virus (21), less activated JNK and more IB␣ were observed after infection with ⌬U L 31 than with the other viruses. Specifically, the IB␣ levels were only 11% relative to mock levels in infections with the ⌬U L 31-R virus, but 63% with ⌬U L 31 at 8 hpi. At 4 and 8 hpi, p-JNK levels in cells infected by ⌬U L 31 were 16% and 45%, respectively, compared to levels in infections with the repair virus. Relevant to this observation, we have noted a delay in viral protein expression in clone 7 cells infected with ⌬U L 31 (data not shown) and an inability of these cells to restore replication to the level seen upon infection with ⌬U L 31-R (21). Thus, the incomplete rescue of ⌬U L 31 replication and protein expression in this cell line correlates with poor JNK and NF-B activation.
ICP27 provided in trans does not rescue the observed defects of ⌬U L 31-infected Vero cells. Previous reports suggested that loss of ICP27 could produce similar defects to those we have observed in characterization of the U L 31 deletion mutant (9, 10) . We therefore examined NF-B and JNK activation and also gC expression in an ICP27-expressing cell line (V27) infected with ⌬U L 31, HSV-1(F), ⌬U L 31-R, or d27-1 (ICP27-null) viruses. Vero cells were used as a control, because V27 is derived from this cell type (30) . The results are presented in Fig. 3 .
In both Vero and V27 cells, JNK activation was decreased in the ⌬U L 31 infection relative to wild-type HSV-1(F) levels. The presence of ICP27 provided in trans (V27 cells) partially rescued JNK activation in both the ⌬U L 31 and ICP27-null virus (d27-1). Specifically, p-JNK protein levels in the ⌬U L 31 and d27-1 infections increased from 15% and 31% (respectively) of wild-type levels at 4 hpi to 50% and 67% (respectively) of wild-type levels at 8 hpi. In contrast, p-JNK protein levels in Vero cells remained at similar levels in cells infected with ⌬U L 31 compared to wild-type infection at 4 and 8 hpi (66% and 59% of wild-type levels, respectively).
ICP4 expression in ⌬U L 31-infected Vero and V27 cells was dramatically reduced compared to wild-type infections in these cell types. At 4 and 8 hpi, ICP4 protein levels in the ⌬U L 31 Vero infections were 0.6% and 54% of wild type, respectively. , and 18 hpi. Proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and reacted with antibodies against p-JNK, total JNK, and IB␣. Antibody to lamin A/C was used as a loading control. Bound antibodies were revealed by reaction with appropriately conjugated antibodies, followed by chemiluminescence and exposure to X-ray film as described in Materials and Methods.
4950
ROBERTS AND BAINES J. VIROL.
The presence of ICP27 provided in trans failed to rescue ICP4 expression for both ⌬U L 31 and ICP27-null (d27-1) infections by 8 hpi. In ⌬U L 31 and d27-1 infections in V27 cells, ICP4 protein levels were only 17% and 8% of wild-type infection (respectively) at 4 hpi and increased to only 23% and 11% of wild-type infection (respectively) at 8 hpi.
Lysates from ⌬U L 31-infected Vero and V27 cells contained readily detectable protein levels of IB␣ at 8 hpi (70% and 119% of mock infection levels, respectively), whereas wild-type infections resulted in IB␣ levels that were only 32% and 16% of those observed in mock infection. This is an indication that NF-B was not activated normally in the ⌬U L 31 infections. ICP27 provided in trans was sufficient to rescue NF-B activation in the ICP27-null virus by 8 hpi, since the IB␣ protein level from the d27-1 infection was only 10% of the mock level. We conclude that ⌬U L 31's defects in protein expression and NF-B and activation cannot be complemented in an ICP27-expressing cell line, and JNK activation is only partially rescued. This suggests that U L 31's contribution to activation of NF-B and JNK is mostly independent of ICP27.
Infection with ⌬U L 31 leads to delayed expression of ICP4 but not failure to initiate infection. One possible explanation of the current results is that the ⌬U L 31 virus is unable to efficiently enter or otherwise infect cells. In this scenario, the observed phenotypes might simply reflect a large number of uninfected cells in the population. To address this possibility, we infected the restrictive Hep2 cell line with the ⌬U L 31 or ⌬U L 31-R viruses at an MOI of 10 PFU per cell. Cells were fixed at 1, 6, and 10 hpi and stained with antibody to ICP4 to visualize infected cells and with Hoechst dye to visualize cellular nuclei. The results are presented in Fig. 4A .
At all time points examined, nuclei were present throughout the visual field. At 1 hpi, no ICP4-specific immunofluorescence was visible in ⌬U L 31-or ⌬U L 31-R infected cells. At 6 hpi many ⌬U L 31-R infected cells exhibited ICP4-specific immunofluorescence, whereas only a few cells infected with ⌬U L 31 displayed such immunostaining. At 10 hpi, many ICP4-positive cells were found throughout the ⌬U L 31-R-and ⌬U L 31-infected cell monolayers. These observations are consistent with the data presented above, indicating that cells infected with wild-type viruses express high levels of ICP4 at early time points, whereas ICP4 expression in ⌬U L 31-infected cells starts at very low levels that increase with time postinfection. The gradual increase in ICP4-expressing cells upon infection with the U L 31 deletion virus cannot be a consequence of cell-to-cell spread within the culture because (i) this would not be expected at 6 hpi and (ii) the U L 31 deletion virus cannot exit noncomplementing cells. A quantification of infection efficiency at 6 hpi and 10 hpi is shown in Fig. 4B . Student's t test demonstrated that the difference in the number of ICP4-expressing cells of total cells was statistically significant (P Ͻ 0.001), whereas this difference was no longer statistically different at 10 hpi (P Ͼ 0.05). The difference at the 6-and 10-hpi time points in ⌬U L 31-infected cells was also statistically dif- The data indicate that U L 31 is expressed at detectable levels as early as 2 hpi. The kinetics of pU L 31 expression early in infection correlated with those of ICP4 expression, whereas at 5 hpi, the amount of pU L 31 increased more dramatically than those of ICP4. Importantly, little or no protein was visible in the CHX-treated lysates, indicating that, as expected, the early detection of pU L 31 is due to active transcription/translation and was not a consequence of its presence within the inoculum. These data indicate that U L 31, previously thought to be expressed only at late times after infection, has low-level expression at early times after infection.
U L 31 expression late in infection is PAA sensitive. Since true late genes are sensitive to DNA polymerase inhibitors, we asked whether pU L 31 expression late in infection was dependent on vDNA synthesis (i.e., sensitive to the DNA polymerase inhibitor PAA). To test this possibility, Hep2 cells were infected with wild-type HSV-1(F) (MOI, 10) or were mock infected in the presence or absence of 200 g/ml PAA. At 12 h postinfection total cell lysates were collected and proteins separated by SDS-PAGE. The immunoblot was reacted with antibody to pU L 31 or lamin A/C as a loading control. The results are presented in Fig. 6 .
The presence of PAA significantly diminished pU L 31 expression in HSV-1-infected cells. These data are consistent with U L 31 expression as a late gene but are not inconsistent with an important role(s) of pU L 31 early in infection.
DISCUSSION
Besides its well-documented role in nuclear egress, the current data argue that pU L 31 plays a role in optimizing viral protein production and activation of JNK and NF-B, especially in Hep2 and HeLa cells. These functions are separable kinetically. Specifically, U L 31 acts to increase early gene expression at times before the activation of JNK and NF-B, which normally occurs at 6 h postinfection with HSV-1. It is therefore unclear whether pU L 31 itself, or another viral protein whose optimal expression depends on pU L 31, is responsible for activation of NF-B and JNK. After 6 h, however, the failure to activate signaling molecules in cells infected with the U L 31-null virus can no longer be kinetically separated from defects in viral gene expression.
The degree to which pU L 31 mediates its effects on viral protein accumulation varies in different cell lines. For example, the block in NF-B and JNK activation is relieved with time in RSC and Vero cells, but less so in Hep2 and HeLa cells. The previously noted restriction of U L 31 deletion mutant replication in Vero cells, and relative permissivity of RSC (21) , is therefore experimentally separable from U L 31-mediated effects on NF-B and JNK activation. We have also shown that the defects of the U L 31 deletion virus cannot be rescued by expression of ICP27 in trans, suggesting that pU L 31 performs different functions than this potent viral regulator. Perhaps most importantly, the effect of pU L 31 on viral protein accumulation can be distinguished from its interaction with pU L 34, because protein expression defects were not observed in cells infected with a U L 34 deletion virus, as noted previously (31) . It follows that because the nuclear lamina is not perforated and particles do not bud from the nuclear membrane in cells in- FIG. 5 . U L 31 expression is detectable early in infection. Hep2 cells were pretreated with 10 M CHX for 1 h at 37°C, 5%CO 2 or left untreated. After the 1-h treatment, cells were infected with 10 PFU per cell of wild-type HSV-1(F) or were mock infected. Cells were incubated an additional hour at 37°C with gentle agitation to allow for viral attachment and entry, and then the overlay was replaced with fresh medium containing 10 M CHX where appropriate. Total cell lysates were collected at 1, 2, 3, and 5 h postinfection, and proteins were separated by SDS-PAGE. The immunoblot was reacted with antibody to pU L 31, ICP4, or lamin A/C. Bound antibodies were revealed by reaction with appropriately conjugated antibodies, followed by chemiluminescence and exposure to X-ray film as described in Materials and Methods.
FIG. 6. U L 31 expression is dependent on viral DNA replication. Hep2 cells were infected with wild-type HSV-1(F) (MOI, 10 PFU per cell) or were mock infected in the presence or absence of 200 g/ml PAA at the start of infection. At 12 hpi, total cell lysates were collected and proteins separated by SDS-PAGE. The immunoblot was reacted with antibody to gC, pU L 31, and lamin A/C. Bound antibodies were revealed by reaction with appropriately conjugated antibodies, followed by chemiluminescence and exposure to X-ray film as described in Materials and Methods.
fected with the U L 34 deletion virus (27, 28, 31) , the function of pU L 31 on protein expression is independent of its roles in nuclear egress or effects on the nuclear lamina. While we do not know the mechanism by which pU L 31 augments viral protein expression and cell signaling, its localization in the nucleoplasm must be sufficient to mediate these functions, because pU L 31 is located solely in the nucleoplasm of cells with the U L 34 deletion virus (28) . Such localization suggests possible roles in transcription, stability, or export of mRNAs, and studies are under way to distinguish between these possibilities. It is possible that the presence of pU L 31 early in infection is important for blocking nascent expression of the NF-B repressor IB␣ during the second wave of NF-B activation (2) . How and which of these putative activities are consequential to (or dependent on) U L 31-dependent JNK and NF-B activation will require further studies. It is logical that incomplete blocks in these processes could be relieved by prolonged incubation, just as we observed in cells infected with the U L 31 deletion virus.
